A clinical trial with two medications, teriparatide and alendronate, evidence an increase in bone mineral density in patients receiving teriparatide compared to those who received alendronate.

In this comparative study, teriparatide seems to show important bone benefits in patients with glucocorticoid-induced osteoporosis, compared to the other drug, in such a way that changes in bone mineral density of the hip, in markers of bone turnover and in bone marrow were detected. number of vertebral fractures.

From this research, whose results are published in "The New England Journal of Medicine" experts concluded that with the teriparatide was associated with a greater increase in bone mineral density of the spine and hip, with significantly fewer new fractures Therefore, teriparatide could be considered as a therapeutic strategy for patients with a high risk of fracture.

One of the treatments for osteoporosis is the use of medications, such as bisphosphonates also used for their prevention in postmenopausal women. The use of glucocorticoids (GC) in the treatment of inflammatory diseases, such as rheumatoid arthritis, is currently the main cause of osteoporosis.

GCs have an inhibitory effect on bone formation in both men and women.

Osteoporosis Shot (November 2019).